Loading…
FTH
Faeth Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology
$33.84+0.30%
Key metrics
- Market cap
- $874.44M
- P/E
- —
- Forward P/E
- —
- P/B
- 5.1x
- Dividend yield
- —
- EPS
- -$60.86
- ROE
- -195.26%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -0.31
- 52-week high
- $37.90
- 52-week low
- $7.45
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.
- 29
- Rockville, United States
Company description provided by Yahoo Finance.